Shandong Buchang Pharmaceuticals Co Ltd (603858) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Buchang Pharmaceuticals Co Ltd (603858) has a cash flow conversion efficiency ratio of -0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-145.26 Million ≈ $-21.26 Million USD) by net assets (CN¥10.07 Billion ≈ $1.47 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 603858 market cap for the company's overall valuation and market capitalisation.
Shandong Buchang Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Shandong Buchang Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shandong Buchang Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Buchang Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Shandong Buchang Pharmaceuticals Co Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Andersons Inc
NASDAQ:ANDE
|
0.359x |
|
Douzone Bizon Co Ltd
KO:012510
|
0.036x |
|
Cadeler A/S
NYSE:CDLR
|
0.025x |
|
Shanghai Huafon Aluminium Corp
SHG:601702
|
-0.011x |
|
BrightGene Bio Medical Technology C
SHG:688166
|
0.010x |
|
Ebos Group Ltd
AU:EBO
|
0.017x |
|
Y.H. Dimri Construction & Development Ltd
TA:DIMRI
|
-0.148x |
|
Billerud AB
ST:BILL
|
0.023x |
Annual Cash Flow Conversion Efficiency for Shandong Buchang Pharmaceuticals Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Buchang Pharmaceuticals Co Ltd from 2011 to 2024. View 603858 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥9.81 Billion ≈ $1.44 Billion |
CN¥939.95 Million ≈ $137.54 Million |
0.096x | +763.71% |
| 2023-12-31 | CN¥11.38 Billion ≈ $1.66 Billion |
CN¥-164.26 Million ≈ $-24.04 Million |
-0.014x | -106.43% |
| 2022-12-31 | CN¥12.28 Billion ≈ $1.80 Billion |
CN¥2.76 Billion ≈ $403.23 Million |
0.224x | +145.65% |
| 2021-12-31 | CN¥14.45 Billion ≈ $2.11 Billion |
CN¥1.32 Billion ≈ $193.23 Million |
0.091x | -35.57% |
| 2020-12-31 | CN¥13.81 Billion ≈ $2.02 Billion |
CN¥1.96 Billion ≈ $286.63 Million |
0.142x | -25.40% |
| 2019-12-31 | CN¥13.79 Billion ≈ $2.02 Billion |
CN¥2.62 Billion ≈ $383.58 Million |
0.190x | +28.47% |
| 2018-12-31 | CN¥13.86 Billion ≈ $2.03 Billion |
CN¥2.05 Billion ≈ $300.10 Million |
0.148x | -0.30% |
| 2017-12-31 | CN¥13.22 Billion ≈ $1.93 Billion |
CN¥1.96 Billion ≈ $287.10 Million |
0.148x | +13.09% |
| 2016-12-31 | CN¥12.71 Billion ≈ $1.86 Billion |
CN¥1.67 Billion ≈ $244.20 Million |
0.131x | -55.07% |
| 2015-12-31 | CN¥7.26 Billion ≈ $1.06 Billion |
CN¥2.12 Billion ≈ $310.33 Million |
0.292x | -27.01% |
| 2014-12-31 | CN¥4.45 Billion ≈ $651.08 Million |
CN¥1.78 Billion ≈ $260.56 Million |
0.400x | +53.90% |
| 2013-12-31 | CN¥4.28 Billion ≈ $626.87 Million |
CN¥1.11 Billion ≈ $163.01 Million |
0.260x | -22.48% |
| 2012-12-31 | CN¥4.02 Billion ≈ $588.56 Million |
CN¥1.35 Billion ≈ $197.43 Million |
0.335x | -39.43% |
| 2011-12-31 | CN¥2.80 Billion ≈ $409.96 Million |
CN¥1.55 Billion ≈ $227.05 Million |
0.554x | -- |
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.